Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor

Katherine D. Watson, Xiaowen Hu, Chun Yen Lai, Heather A. Lindfors, Dana D. Hu-Lowe, Theresa A. Tuthill, David R. Shalinsky, Katherine W. Ferrara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80% contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r 2 = 0.86.

Original languageEnglish (US)
Pages (from-to)909-921
Number of pages13
JournalUltrasound in Medicine and Biology
Volume37
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Vascular Endothelial Growth Factor Receptor
inhibitors
tumors
replenishment
Contrast Media
Neoplasms
flow velocity
Protein-Tyrosine Kinases
tyrosine
Adenocarcinoma
Breast
Magnetic Resonance Spectroscopy
Perfusion
rats
destruction
magnetic resonance
Growth
gradients
estimates

Keywords

  • AG-028262
  • CPS
  • Destruction-replenishment ultrasound
  • Dynamic contrast-enhanced MRI
  • Perfusion
  • Tumor blood flow
  • VEGF-R

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Biophysics

Cite this

Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor. / Watson, Katherine D.; Hu, Xiaowen; Lai, Chun Yen; Lindfors, Heather A.; Hu-Lowe, Dana D.; Tuthill, Theresa A.; Shalinsky, David R.; Ferrara, Katherine W.

In: Ultrasound in Medicine and Biology, Vol. 37, No. 6, 06.2011, p. 909-921.

Research output: Contribution to journalArticle

Watson, Katherine D. ; Hu, Xiaowen ; Lai, Chun Yen ; Lindfors, Heather A. ; Hu-Lowe, Dana D. ; Tuthill, Theresa A. ; Shalinsky, David R. ; Ferrara, Katherine W. / Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor. In: Ultrasound in Medicine and Biology. 2011 ; Vol. 37, No. 6. pp. 909-921.
@article{72723eb8c91d4bbe8edd68e889275fb0,
title = "Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor",
abstract = "We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80{\%} contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r 2 = 0.86.",
keywords = "AG-028262, CPS, Destruction-replenishment ultrasound, Dynamic contrast-enhanced MRI, Perfusion, Tumor blood flow, VEGF-R",
author = "Watson, {Katherine D.} and Xiaowen Hu and Lai, {Chun Yen} and Lindfors, {Heather A.} and Hu-Lowe, {Dana D.} and Tuthill, {Theresa A.} and Shalinsky, {David R.} and Ferrara, {Katherine W.}",
year = "2011",
month = "6",
doi = "10.1016/j.ultrasmedbio.2011.03.001",
language = "English (US)",
volume = "37",
pages = "909--921",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor

AU - Watson, Katherine D.

AU - Hu, Xiaowen

AU - Lai, Chun Yen

AU - Lindfors, Heather A.

AU - Hu-Lowe, Dana D.

AU - Tuthill, Theresa A.

AU - Shalinsky, David R.

AU - Ferrara, Katherine W.

PY - 2011/6

Y1 - 2011/6

N2 - We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80% contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r 2 = 0.86.

AB - We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80% contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r 2 = 0.86.

KW - AG-028262

KW - CPS

KW - Destruction-replenishment ultrasound

KW - Dynamic contrast-enhanced MRI

KW - Perfusion

KW - Tumor blood flow

KW - VEGF-R

UR - http://www.scopus.com/inward/record.url?scp=79956071970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956071970&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2011.03.001

DO - 10.1016/j.ultrasmedbio.2011.03.001

M3 - Article

C2 - 21531499

AN - SCOPUS:79956071970

VL - 37

SP - 909

EP - 921

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 6

ER -